Equality and discrimination
Regulator to rewrite standards in drive to tackle inequalities for preregistration candidates
The General Pharmaceutical Council calls for pharmacy schools to be more proactive on equality and diversity after preregistration exam results show differentials in pass rates for various racial groups.
The pharmacy regulator has promised a rewrite of its standards to ensure “equality of opportunity” for all preregistration pharmacists, following data showing large differentials in pass rates by sex and age, and reports of “overt racism” during training.
In a drive to tackle variability in performance by preregistration exam candidates, the General Pharmaceutical Council (GPhC) has announced that it will require pharmacy schools to be more “proactive” on equality and diversity.
The GPhC has also said that it plans to discuss equality and diversity practices with all preregistration training providers.
, held on 12 July 2018, set out how an analysis of preregistration exam results since 2013 — broken down by categories including age, sex, ethnicity and which school of pharmacy the student attended — highlighted a ”marked difference in performance by ethnicity”, with the performance of black African candidates “tending to be low”.
On 5 February 2016, found examples of “explicit prejudice and perceptions of implicit bias” towards black African students, particularly those from abroad, and suggested that this may be contributing to lower pass rates among this ethnic group.
The report also said that bias, “whether overt or implied”, undermined some black African students’ ability to learn, develop and reach their full potential.
Results from the 2017 preregistration exams show that white candidates had the highest pass rate (93.6%), and those with Pakistani (72.1%) or black African (65.6%) ethnicity had the lowest pass rates.
The GPhC also said that older candidates — in particular those aged over 35 years — and those specialising in community pharmacy had significantly lower pass rates in the preregistration exam, and there was variation between training providers and pharmacy schools.
The paper, presented to the council on 12 July 2018, said: “a consistent theme in this paper has been variability in performance by candidates and, linked to that, equality of opportunity.
“It seems logical, therefore, that the actions arising from our data analysis should focus on equality and diversity. With that in mind, we have identified three actions for us to take forward which we think build effectively on what we have learned from our analyses.”
The GPhC said it plans to “redraft its current initial education and training standards for pharmacists to require schools of pharmacy to have proactive equality and diversity policies and for schools to report on the implementation of them through accreditation” later in 2018.
The GPhC also said it would ask preregistration trainers to discuss their equality and diversity practices as it vows to tackle equality of opportunity among trainee pharmacists.
Some council members said the GPhC should bring in external expertise when considering equality and diversity issues . Council member Mark Hammond, visiting professor in public policy at Canterbury Christ Church University, suggested bringing in external expertise because of the “long running nature” of these issues.
“It would provide an additional level of validation and expertise, and demonstrate how seriously we take this,” he said.
Citation: The Salvadore DOI: 10.1211/PJ.2018.20205182
Recommended from Pharmaceutical Press
Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.£47.00
A complete source of current information about the US health care system. Includes concise reports on trends, regulations, policy and finances.£49.00
This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.£48.00
This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.£43.00
An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.£54.00